Pancreatic cancer is one of the deadliest forms of cancer, largely because it’s so difficult to catch early. By the time it’s ...

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood ...

Mainz Biomed has the exclusive rights to develop a test for early pancreatic cancer detection using Liquid Biosciences' biomarkers.

Furthermore, existing biomarkers, such as CA19-9, are not reliable on their own to detect early-stage pancreatic cancer. Goel, Xu, and colleagues explored the potential of an exosome-based liquid ...

The biomarkers, identified using Liquid's EMERGE platform, demonstrated a 95% sensitivity and 98% specificity in detecting pancreatic cancer across multiple study cohorts. These promising results ...

has entered into an exclusive licensing agreement with Liquid Biosciences to develop a blood test for the detection of pancreatic cancer. The test utilizes a portfolio of mRNA biomarkers and a ...

A new blood test could diagnose pancreatic cancer ... As with most types of cancer, once the tumor has spread, it becomes much harder to successfully treat. “Liquid biopsy” tests which use ...

Opens in a new tab or window The blood test achieved high accuracy, with 98% specificity and 73% sensitivity for detecting pancreatic ... of proteins in liquid biopsy-based cancer detection ...

Discovery Analysis Demonstrates Transformative Sensitivity of 95% with Specificity of 98% for the Detection of Pancreatic Cancer in Blood ... Algorithm Based on Liquid Biosciences EMERGE Platform ...